Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neural Response to Inflammatory Challenge in MDD
NCT04751331Phase 2Recruiting
- Start
- May 2021
- Primary completion
- Apr 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lipopolysaccharide endotoxin (4 arms). Primary endpoint: Inflammatory response at 1.5 hours. Started May 2021; status: recruiting.
02
Drugs
lipopolysaccharide endotoxin
Beyond the preview
Go deeper on NCT04751331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751331.